David Bearden1, Andrew P Steenhoff, Dennis J Dlugos, Dennis Kolson, Parth Mehta, Sudha Kessler, Elizabeth Lowenthal, Baphaleng Monokwane, Gabriel Anabwani, Gregory P Bisson. 1. *Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA; †Botswana-UPenn Partnership, Philadelphia, PA; ‡Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; §Division of Infectious Disease, Children's Hospital of Philadelphia, Philadelphia, PA; ‖Division of Neurology, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA; ¶Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX; #Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; **Department of Pediatrics, University of Botswana, Gaborone, Botswana; ††Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana; and ‡‡Division of Infectious Disease, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.
Abstract
BACKGROUND: Seizures are common among patients with HIV/AIDS in the developing world and are associated with significant morbidity and mortality. Early treatment with combination antiretroviral therapy (cART) may reduce this risk by decreasing rates of central nervous system infections and HIV encephalopathy. METHODS: A case-control study of new-onset epilepsy among children aged 0-18 years with perinatally acquired HIV/AIDS followed in Gaborone, Botswana, during the period 2003-2009 was conducted. Children with epilepsy were identified and compared with age- and sex-matched controls without epilepsy with respect to timing of cART initiation. Early treatment was defined as treatment with cART before the age of 12 months, at a CD4% of greater than 25 in children aged 1-5 years, or at an absolute CD4 count of >350 cell per cubic millimeter in children aged 5 years and older. RESULTS: We identified 29 cases of new-onset epilepsy and 58 age- and sex-matched controls. The most common identified etiologies for epilepsy were central nervous system infections and direct HIV neurotoxicity. Only 8 (28%) of the children who developed epilepsy received early treatment compared with 31 (53%) controls (odds ratio: 0.36, 95% confidence interval: 0.14 to 0.92, P = 0.03). This effect was primarily driven by differences in rates of epilepsy among children who initiated treatment with cART between the ages of 1 and 5 years (11% vs. 53%, odds ratio: 0.11, 95% confidence interval: 0.01 to 1.1, P = 0.06). CONCLUSIONS: Earlier initiation of cART may be protective against epilepsy in children with HIV.
BACKGROUND: Seizures are common among patients with HIV/AIDS in the developing world and are associated with significant morbidity and mortality. Early treatment with combination antiretroviral therapy (cART) may reduce this risk by decreasing rates of central nervous system infections and HIV encephalopathy. METHODS: A case-control study of new-onset epilepsy among children aged 0-18 years with perinatally acquired HIV/AIDS followed in Gaborone, Botswana, during the period 2003-2009 was conducted. Children with epilepsy were identified and compared with age- and sex-matched controls without epilepsy with respect to timing of cART initiation. Early treatment was defined as treatment with cART before the age of 12 months, at a CD4% of greater than 25 in children aged 1-5 years, or at an absolute CD4 count of >350 cell per cubic millimeter in children aged 5 years and older. RESULTS: We identified 29 cases of new-onset epilepsy and 58 age- and sex-matched controls. The most common identified etiologies for epilepsy were central nervous system infections and direct HIV neurotoxicity. Only 8 (28%) of the children who developed epilepsy received early treatment compared with 31 (53%) controls (odds ratio: 0.36, 95% confidence interval: 0.14 to 0.92, P = 0.03). This effect was primarily driven by differences in rates of epilepsy among children who initiated treatment with cART between the ages of 1 and 5 years (11% vs. 53%, odds ratio: 0.11, 95% confidence interval: 0.01 to 1.1, P = 0.06). CONCLUSIONS: Earlier initiation of cART may be protective against epilepsy in children with HIV.
Authors: Mark F Cotton; Avy Violari; Kennedy Otwombe; Ravindre Panchia; Els Dobbels; Helena Rabie; Deirdre Josipovic; Afaaf Liberty; Erica Lazarus; Steve Innes; Anita Janse van Rensburg; Wilma Pelser; Handre Truter; Shabir A Madhi; Edward Handelsman; Patrick Jean-Philippe; James A McIntyre; Diana M Gibb; Abdel G Babiker Journal: Lancet Date: 2013-11-09 Impact factor: 79.321
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Isabel A Michaelis; Maryke Nielsen; Craig Carty; Markus Wolff; Caroline A Sabin; John S Lambert Journal: South Afr J HIV Med Date: 2020-06-30 Impact factor: 2.744
Authors: David R Bearden; Baphaleng Monokwane; Esha Khurana; James Baier; Esther Baranov; Kate Westmoreland; Loeto Mazhani; Andrew P Steenhoff Journal: Pediatr Neurol Date: 2016-03-17 Impact factor: 3.372
Authors: Mathura Ravishankar; Ifunanya Dallah; Manoj Mathews; Christopher M Bositis; Musaku Mwenechanya; Lisa Kalungwana-Mambwe; David Bearden; Allison Navis; Melissa A Elafros; Harris Gelbard; William H Theodore; Igor J Koralnik; Jason F Okulicz; Brent A Johnson; Clara Belessiotis; Ornella Ciccone; Natalie Thornton; Melissa Tsuboyama; Omar K Siddiqi; Michael J Potchen; Izukanji Sikazwe; Gretchen L Birbeck Journal: Epilepsia Open Date: 2022-04-01